Ipsilateral Breast Cancer Recurrence: Characteristics, Treatment, and Long-Term Oncologic Results at a High-Volume Center.


Journal

Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731

Informations de publication

Date de publication:
08 2021
Historique:
received: 16 11 2020
revised: 10 12 2020
accepted: 13 12 2020
pubmed: 13 1 2021
medline: 20 1 2022
entrez: 12 1 2021
Statut: ppublish

Résumé

Salvage mastectomy is considered the treatment of choice for ipsilateral breast cancer recurrence (IBCR), even if a second breast-conserving surgery (BCS) is feasible. The purpose of this study was to describe the characteristics of IBCR patients, to compare the 2 therapeutic options in terms of long-term outcomes, and to identify independent factors that may predict the type of treatment. A total of 309 IBCR patients who underwent either repeat BCS or mastectomy were identified. All the analyzed patients with IBCR had true recurrence. Repeat BCS and salvage mastectomy were performed in 143 and 166 patients, respectively. Age < 65 years (59.6% vs 37.1% if age ≥ 65 years; odds ratio, 2.374; 95% confidence interval, 0.92-5.24; P = .018) and disease-free interval < 24 months (15.7% vs 10.5% if disease-free interval ≥ 24 months; odds ratio, 2.705; 95% confidence interval, 1.42-5.97; P = .007) were found to significantly increase the probability of receipt of mastectomy. Disease-free survival rates at 3, 5, and 10 years were 79.2%, 68.2%, and 36.9%; and 77.2%, 65.9%, and 55.3% in patients receiving repeat BCS or mastectomy, respectively (P = .842). Overall survival rates at 3, 5, and 10 years were 95.4%, 91.4%, and 68.5%; and 87.3%, 69.3%, and 57.9%, respectively, in patients receiving repeat BCS or mastectomy (P = .018). Salvage mastectomy should not be considered the only treatment option for IBCR. A second BCS can still be evaluated and proposed to IBCR patients, with acceptable locoregional control and survival. The risk of poor long-term prognosis after mastectomy should be shared with the patient.

Identifiants

pubmed: 33431329
pii: S1526-8209(20)30334-7
doi: 10.1016/j.clbc.2020.12.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

329-336

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Andrea Sagona (A)

Breast Unit, Humanitas Clinical and Research Center-IRCCS, Milan, Italy.

Damiano Gentile (D)

Breast Unit, Humanitas Clinical and Research Center-IRCCS, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy. Electronic address: damiano.gentile@humanitas.it.

Chiara Annunziata Pasqualina Anghelone (CAP)

Breast Unit, Humanitas Clinical and Research Center-IRCCS, Milan, Italy.

Erika Barbieri (E)

Breast Unit, Humanitas Clinical and Research Center-IRCCS, Milan, Italy.

Emilia Marrazzo (E)

Breast Unit, Humanitas Clinical and Research Center-IRCCS, Milan, Italy.

Lidija Antunovic (L)

Department of Nuclear Medicine, Humanitas Clinical and Research Center-IRCCS, Milan, Italy.

Davide Franceschini (D)

Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Center-IRCCS, Milan, Italy.

Corrado Tinterri (C)

Breast Unit, Humanitas Clinical and Research Center-IRCCS, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH